がん免疫療法における免疫関連有害事象発症のメカニズム解明
がん免疫療法における免疫関連有害事象発症のメカニズム解明
批准号:
21K08152
负责人:
コーチン ビタリー
金额:
$2.58万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2021
资助国家:
日本
项目状态:
已结题
起止时间:
2021-04-01 至 2024-03-31
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Immune Related Adverse Events (irAEs) restrain ICIs use. The irAEs are caused by ICI-induced autoimmunity against self-tissues by auto-antibody (Ab) or self-reacting T cells. We found GPRC5A-derived peptide epitope presented by HLA-A24 specifically in human lung cells and currently investigating whether autoreactive T cells and/or Ab to GPRC5A may be responsible for the inflammation and damage in lung tissue of patients who underwent treatment with ICIs.We use HLA-A24 transgenic MHC-KO mice (A24-Tg mice) as a model. We have confirmed that the lung tissue of the A24-Tg animals express HLA-A24 and can process and present GPRC5A-derived peptide epitope identical to the one in human cells.
期刊论文(2)
专著(0)
科研奖励(0)
会议论文
DOI:
10.1016/j.celrep.2022.110331
发表时间:
2022-02-01
期刊:
CELL REPORTS
影响因子:
8.8
作者:
[Nagasaki, Joji, Inozume, Takashi, Togashi, Yosuke]
通讯作者:
Togashi, Yosuke
国内基金
海外基金
PD-1疗法通过Tfh细胞途径促进肺鳞癌患者irAEs进展的机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:施伟伟
-
依托单位: